20th International Congress » Neuropharmacology

12:00pm-1:30pm

A computational model of iron transport between the blood circulation and the brain

V. Tjendana-Tjhin, S. Mitchell, E.A. Milward, M.J. Chappell, J.F. Collingwood (Coventry, United Kingdom)

12:00pm-1:30pm

Amelioration of αLPHA-synuclein aggregation and motor behavior deficits by apocyanin in intranigral lipopolysaccharide induced animal model of Parkinson’s disease

B. Nehru, N. Sharma (Chandigarh, India)

12:00pm-1:30pm

AMP kinase regulates ligand-gated K-ATP channels in substantia nigra dopamine neurons

S.W. Johnson, Y. Wu, A.C. Munhall, K.Z. Shen (Portland, OR, USA)

12:00pm-1:30pm

An ongoing phase 2, multi-centre, open-label, study of WTX101 in Wilson disease patients – Early observations

A. Czlonkowska, K.H. Weiss, A. Ala, F. Askari, D. Nicholl, M.L. Schilsky (Warsaw, Poland)

12:00pm-1:30pm

AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, W.K.D. Ko, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

12:00pm-1:30pm

Autophagic modulation by rosuvastatin prevent rotenone induced neurotoxicity as an in vitro model of Parkinson’s disease

W. Jang (Gangneung, Korea)

12:00pm-1:30pm

Clinical characterization of pramipexole induced edema in Parkinson’s disease (PD). Is it always the best option discontinue the treatment?

E. Urrea-Mendoza, F.J. Revilla (Greenville, SC, USA)

12:00pm-1:30pm

Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard, S. Hogg (Manchester, United Kingdom)

12:00pm-1:30pm

Cognitive effects of pramipexole in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease

E.Y. Pioli, S.M.J. Camus, J. Yang, Q. Li, A. Crossman, E. Bezard (Manchester, United Kingdom)

12:00pm-1:30pm

Combinative therapy of memantine and galantamine hydrobromide as a tool of choice for the treatment of vascular parkinsonism with early appearance of dementia symptoms

A. Turakhanov, S. Dadajonov, R. Sadikov, R. Khodjaev, S. Nurov (Tashkent, Uzbekistan)

12:00pm-1:30pm

Curcumin supplementation improves motor dysfunction in lipopolysaccharide induced Parkinon’s disease model: Possible biochemical, neurochemical and immunohistochemical alterations in rats

N. Sharma, B. Nehru (Chandigarh, India)

12:00pm-1:30pm

Dopaminergic medicines are alternative drugs for treatment of motor disorders in ischemic stroke

A. Azimov, R. Sadykov, G. Rakhimbaeva, S. Dadajonov, O. Azizova (Tashkent, Uzbekistan)

12:00pm-1:30pm

Efficacy and safety of tetrabenazine in hyperkinetic movements disorders- An observational study

R. Miguel, M. Mendonça, R. Barbosa, F. Ladeira, T. Lampreia, J. Vale, P. Bugalho (Lisbon, Portugal)

12:00pm-1:30pm

Hydrogen sulfide functions as a neuromodulator to regulate striatal neurotransmission in a mouse model of Parkinson’s disease

L. Zhang, M. Wang, J. Zhu, Y. Pan, J. Dong (Nanjing, People's Republic of China)

12:00pm-1:30pm

Inhibition of cathepsin D enhances the autophagy lysosome pathway dysfunction and α-synuclein aggregation in experimental parkinsonism

L. Li, Y.P. Yang, L. Gao, Y. Song, Z. Liang (Suzhou, People's Republic of China)

12:00pm-1:30pm

Long-term effects of levodopa/carbidopa intestinal gel infusion in advanced Parkinson’s disease patients: Dutch multicenter retrospective cohort study

H.R. Moes, J. Groenendal-Laurensse, M. Drent, G. Tissingh, T. van Laar (Groningen, Netherlands)

12:00pm-1:30pm

May early introduction of dopaminergic agonists improve simptoms after ischemic stroke? The interim report

J. Kobal, Z. Melik, K. Cankar (Ljubljana, Slovenia)

12:00pm-1:30pm

Neuroprotection effect of an endogenous amine, 1MeTIQ against disturbances in dopamine release induced by the neurotoxin, 6-OHDA: In vivo microdialysis study

A. Wasik, I. Romanska, L. Antkiewicz-Michaluk (Krakow, Poland)

12:00pm-1:30pm

Neuroprotective and antidepressant-like effects of the endogenous amines from tetrahydroisoquinoline group TIQ and 1MeTIQ in the animal model of depressive disorder: Behavioral and neurochemical studies in the rat

L.R. Antkiewicz-Michaluk (Krakow, Poland)

12:00pm-1:30pm

Priapism and hypersexuality associated with rotigotine in an elderly Parkinsonian patient: A case report

A. Cannas, M. Meloni, M.M. Mascia, P. Solla, G. Orofino, R. Farris, D. Ciaccio, E. Binaghi, F. Marrosu (Nuoro, Italy)

12:00pm-1:30pm

Selective M4 antagonism potentiates L-DOPA-induced dyskinesia in MPTP-treated common marmosets

D. Klisko, R. Fisher, L. Lincoln, P. Jenner, S. Rose (London, United Kingdom)

12:00pm-1:30pm

Sensorimotor impairments and the excitability of spinal cord in lead intoxicated rat during development and a potent restorative effect of curcumin

H. Benammi, O. El Hiba, H. Gamrani (Marrakesh, Morocco)

12:00pm-1:30pm

Targeting PDE7 by the small molecule S14: A potential disease-modifying Parkinson�s disease therapy ready to start clinical trials

A. Martinez, C. Gil, D. Lopez Ribas, E. Cunchillos, J. Domenech, M. Sarasa (Madrid, Spain)

12:00pm-1:30pm

The neurosteroid dehydroepiandrosterone sulfate (DHEAS) reverses the dopaminergic deficiencies in mild hepatic encephalopathy: A possible therapeutic issue for the management of parkinsonism in cirrhotic patients

O. El Hiba, H. Gamrani (Marrakesh, Morocco)

12:00pm-1:30pm

The role and underlying mechanisms of BAG3 in regulating autophagy in PC12 cells

Y.P. Yang, Y.L. Cao, C.J. Mao, F. Wang, L.F. Hu, C.F. Liu (Suzhou, People's Republic of China)

12:00pm-1:30pm

The unfolded protein response pathway as a possible therapeutic target for the synucleinopathies

J.H. Baek, E. Bereczki, D. Aarsland (Stockholm, Sweden)